Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

Otsuka

The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Otsuka's 2012 sales performance.

Otsuka

Otsuka’s Alzheimer’s agitation drug hits the mark

Otsuka’s Alzheimer’s agitation drug hits the mark Otsuka has reported positive phase 3 results with a drug intended to calm agitation in patients with Alzheimer’s disease. ... All three drug classes have side effect issues, including drowsiness. AVP-786 – developed by Otsuka subsidiary Avanir in

Deal Watch October 2018

hormone deficiency. Acquisition of. product rights. $145m. Proteus Digital Health/. Otsuka.

Sanofi swaps execs with Bayer, looks to staunch diabetes, cardio decline

Sanofi swaps execs with Bayer, looks to staunch diabetes, cardio decline Dieter Weinand joins Sanofi on 1 November, and will be based in the US in Bridgewater, New Jersey, where he had earlier held a senor role with Otsuka.

Daily Brief: Cellectis gains Novartis scientist, EU label updates for Janssen and Otsuka

Daily Brief: Cellectis gains Novartis scientist, EU label updates for Janssen and Otsuka Otsuka gains European nod for Jinarc extension. The European Commission has approved a label extension for Jinarc (tolvaptan) to include adult patients with CKD stage 4 Autosomal Dominant Polycystic Kidney Disease

Indivior push to diversify boosted by schizophrenia drug approval

Indivior push to diversify boosted by schizophrenia drug approval Perseris will face competition from Lundbeck/Otsuka’s Abilify Maintena and J&J’s Invega Sustenna. ... It will launch in competition to other monthly therapies, such as Lundbeck/Otsuka’s market leading Abilify Maintena (aripiprazole) and Johnson

[ Previous 5 results ] 1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Nucleus Global

Nucleus Global is the largest specialist medical communications network in the world. Globally, we have over 800 experts delivering world-class...

Latest intelligence

Personalised medicine: driving a need for greater diversity in clinical trials
Kate Shaw, Innovative Trials' Founder & CEO, investigates one of the biggest challenges facing clinical research today....
Congresses and conferences
Superstar congresses and conferences will stay centre stage but now share the limelight with virtual and hybrid events
With the pandemic having dimmed the lights on pharma conferences, their virtual and hybrid replacements have grasped the opportunity and are here to stay...
Cervical Cancer Prevention Month
In this first 2022 blog, the Innovative Trials' Equality & Diversity committee will be looking at raising awareness around Cervical Cancer...